Deproteinized hemoderivate - instructions for use, dose, side effects, contraindications

Hemoderivat obtained by dialysis and ultrafiltration contains substances with molecular weight less than 5000 Daltons (Ya). Accelerates the processes of utilization of oxygen and glucose at the molecular level.Strengthening the energy metabolism, ensures the stability of cells to hypoxia in conditions of ischemia. It normalizes pH, accelerates blood circulation, decomposition of beta-hydroxybutyrate and lactate, improves tissue trophism.

Pharmacokinetics:

After parenteral administration, the therapeutic effect develops after 30 minutes and lasts for 3 hours.

Indications:

It is used to treat metabolic and circulatory disorders of the central nervous system: with ischemic stroke, craniocerebral trauma, encephalopathy of various genesis. It is used for violations of peripheral arterial and venous circulation, angiopathy, including diabetes mellitus. Used to regenerate tissues for ulcers, bedsores, burns, radiation damage to the skin and mucous membranes. It is used to treat radiation neuropathy.

ICD-10

IX.I20-I25.I25.2 Postponed myocardial infarction

IX.I60-I69.I63 Cerebral infarction

IX.I60-I69.I67.9 Cerebrovascular disease, unspecified

IX.I60-I69.I69 Effects of cerebrovascular disease

IX.I70-I79.I73.9 Peripheral vascular disease, unspecified

IX.I70-I79.I79.2 * Peripheral angiopathy in diseases classified elsewhere

IX.I80-I89.I87.2 Venous insufficiency (chronic) (peripheral)

IX.I95-I99.I99 Other and unspecified disorders of the circulatory system

XII.L55-L59.L58 Radiation dermatitis radiation

XII.L80-L99.L89 Decubital ulcer

XIV.N30-N39.N30.4 Radiation cystitis

XIX.S00-S09.S06 Intracranial injury

XIX.T08-T14.T14.1 Open wound of unspecified area of the body

XIX.T20-T32.T30 Thermal and chemical burns, unspecified

XIX.T79.T79.3 Post-traumatic wound infection, not elsewhere classified

VI.G60-G64.G63.2 * Diabetic polyneuropathy (E10-E14 + with common fourth sign .4)

Contraindications:

Severe cardiovascular failure, oliguria, anuria, pulmonary edema, fluid retention in the body, individual intolerance.

Carefully:

Pregnancy and lactation, hypernatremia, hyperchloremia, hypersensitivity.

Pregnancy and lactation:

Recommendations for FDA - Category B. Applicable with caution, in cases where the expected effect exceeds the risk to the fetus and newborn.

Dosing and Administration:

Use in children

Intramuscularly or intravenously:

newborns and children under 3 years of age - 0.4-0.5 ml / kg once a day;

3-6 years - 0.25-0.4 mg / kg once a day.

Adults

Intravenous drip or jet, intraarterially - 5-20 ml per day. Intramuscularly, slowly - no more than 5 ml per day.

The highest daily dose: 2 g of dry matter per 250 ml of 5% solution dextrose or 0.9% sodium chloride.

Side effects:

Allergic reactions.

Overdose:

Cases of overdose are not described.

Treatment is symptomatic.

Interaction:

Clinically significant interactions are not described.

Special instructions:

The drug is on the anti-doping control list.

Instructions

Deproteinized hemoderivat (Deproteinized calf blood extract)